HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iacopetta, B Articles by Watanabe, T Search for Related Content PubMed PubMed Citation Articles by Iacopetta, B Articles by Watanabe, T Topic Collections Related Articles

Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

¹ School of Surgery and Pathology, University of Western Australia, Western Australia, Australia
² Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan

Correspondence to:
Correspondence to:
Dr B Iacopetta
School of Surgery and Pathology M507, University of Western Australia, 35 Stirling Hwy, Nedlands 6009, Australia; barry.iacopetta@uwa.edu.au

Keywords: 5-fluorouracil; colorectal cancer; microsatellite instability; adjuvant chemotherapy

The first 150 words of the full text of this article appear below.

We read with interest the study by Jover and colleagues (Gut 2006;55:848–55) on the predictive value of the DNA mismatch repair (MMR) or microsatellite instability (MSI) phenotype for response of colorectal cancer patients to 5-fluorouracil (5-FU) chemotherapy. We are concerned however about the conclusion reached by the authors and the accompanying commentary (Gut 2006;55:759–61) that MSI status should be considered in decisions on the use of 5-FU. While the clinical utility of MSI status for screening of hereditary non-polyposis colorectal cancer (HNPCC) is unquestioned, we are of the opinion that currently available data cannot justify exclusion of patients with MSI tumours from receiving 5-FU treatment.

The authors state that "5-FU based chemotherapy may not be useful in stage II and III MMR deficient colorectal cancer and a revision in the management of this subgroup should be considered". However, examination of the results . . . [Full text of this article]

Related Articles

Authors’ reply

J M Carethers
Gut 2006 55: 1819. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				K. Imai and H. Yamamoto Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics Carcinogenesis, April 1, 2008; 29(4): 673 - 680. [Abstract] [Full Text] [PDF]